By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regen BioPharma  

4700 Spring Street
Suite 304
La Mesa  California  91942  U.S.A.
Phone: 619-702-1404 Fax: 619-330-2328


Company News
Regen BioPharma 's HemaXellerate Therapy For Treating Aplastic Anemia Licensed For Proof Of Concept Study 4/28/2016 6:18:18 AM
Regen BioPharma Series A Preferred Stock Begins Trading Under The Symbol RGBPP On The OTC PINK 4/21/2016 6:31:40 AM
Regen BioPharma Submits IND Application To FDA On tCellVax, A Checkpoint Inhibitor For Cancer Therapy 3/23/2016 6:46:59 AM
Regen BioPharma Completes Preclinical Experimentation For Its siRNA NR2F6 Checkpoint Inhibitor 2/24/2016 6:55:27 AM
Regen BioPharma 's Immune Checkpoint Inhibitor Found To Stimulate Key Immune System Proteins Interleukin-17 And Interleukin-18 2/17/2016 6:52:19 AM
Regen BioPharma Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell For Solid Tumors 2/3/2016 6:51:20 AM
Regen BioPharma Submits Application To FDA For Orphan Drug Designation For Its HemaXellerate Product 1/26/2016 6:51:52 AM
Regen BioPharma And The NIH To Collaborate 1/20/2016 7:31:42 AM
Regen BioPharma President Harry Lander Provides Open Letter To Shareholders On Company's Progress And Developments 1/14/2016 8:00:26 AM
Regen BioPharma Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6 12/16/2015 9:35:44 AM